Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Source avec lien : New England Journal of Medicine, 383(27), . 10.1056/NEJMoa2034577

L’infection par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) et la maladie coronavirale 2019 (Covid-19) qui en résulte ont touché des dizaines de millions de personnes dans le cadre d’une pandémie mondiale. Des vaccins sûrs et efficaces sont nécessaires de toute urgence.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.

Lisez l’article

Laisser un commentaire